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Zymogens are delivered to the arterial wall by radial transmural convection. Plasminogen
can be activated within the arterial wall to produce plasmin, which is involved in evolution
of the atherosclerotic plaque. Vascular smooth muscle cells (vSMCs) protect the vessels
from proteolytic injury due to atherosclerosis development by highly expressing endocytic
LDL receptor-related protein-1 (LRP-1), and by producing anti-proteases, such as
Protease Nexin-1 (PN-1). PN-1 is able to form covalent complexes with plasmin. We
hypothesized that plasmin-PN-1 complexes could be internalized via LRP-1 by vSMCs
during the early stages of human atheroma. LRP-1 is also responsible for the capture of
aggregated LDL in human atheroma. Plasmin activity and immunohistochemical analyses
of early human atheroma showed that the plasminergic system is activated within the
arterial wall, where intimal foam cells, including vSMCs and platelets, are the major sites
of PN-1 accumulation. Both PN-1 and LRP-1 are overexpressed in early atheroma at
both messenger and protein levels. Cell biology studies demonstrated an increased
expression of PN-1 and tissue plasminogen activator by vSMCs in response to LDL.
Plasmin-PN-1 complexes are internalized via LRP-1 in vSMCs, whereas plasmin alone is
not. Tissue PN-1 interacts with plasmin in early human atheroma via two complementary
mechanisms: plasmin inhibition and tissue uptake of plasmin-PN-1 complexes via LRP-1
in vSMCs. Despite this potential protective effect, plasminogen activation by vSMCs
remains abnormally elevated in the intima in early stages of human atheroma.
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INTRODUCTION
The arterial wall is the target of plasma-borne components such as low density lipoprotein (LDL)
(Tabas et al., 2007) and circulating zymogens (Lacolley et al., 2012). Like LDL, circulating zymogens
and proforms are delivered to the adjacent arterial wall by radial transmural hydraulic conductance
(Caro and Lever, 1984; Caro, 2009). In addition to their role in clot lysis, tumoral cell mobilization,
and metastasis (Didiasova et al., 2014), enzymes of the fibrinolytic system are involved in the
chronic evolution of the plaque at the initial stage of atherosclerotic disease (Torzewski et al., 2004),
including migration and loss of vascular smooth muscle cells (vSMCs) by pericellular proteolysis
(Meilhac et al., 2003). Plasminogen can be activated on the vSMC membrane platform by t-PA
Boukais et al. Protease Nexin-1 and Early Atheroma
(tissue plasminogen activator) and u-PA (urokinase) release
(Borges et al., 2010). vSMCs also produce antiproteases to protect
the vascular wall from proteolytic injury (Gomez et al., 2013).
Among these antiproteases, significant quantities of serpins,
such as Protease Nexin-1 (PN-1) (Bouton et al., 2003) and
plasminogen activator inhibitor-1 (PAI-1), in parallel with tissue
inhibitors of metalloproteinases (TIMPs), are known to be
expressed by vSMCs (Bouton et al., 2012). PN-1 has emerged
as an important actor in the regulation of proteolytic tissue
degradation since it is a powerful inhibitor of several serine
proteases, including thrombin, plasminogen activators (u-PA,
t-PA), and plasmin. PN-1 is able to limit the pericellular
activity of plasmin by protecting vSMCs against cell detachment
and death (Meilhac et al., 2003; Rossignol et al., 2004). PN-
1, a tissue serpin, is poorly diffusible due to its retention
by glycosaminoglycans (GAGs) at the cell surface, thereby
being barely detectable in the plasma (Bouton et al., 2012).
PN-1 is synthesized and secreted under basal conditions by
vSMCs, where its expression is up-regulated by mechanical
load (Bouton et al., 2003) and transforming growth factor β
(TGFβ) (Gomez et al., 2013) or down-regulated by thrombin
(Richard et al., 2004). Overexpression of PN-1 limits spreading
and migration of vSMCs (Richard et al., 2006). Platelets and
phagocytes are also important sources of PN-1 in intraplaque
hemorrhages (Mansilla et al., 2008), able to limit fibrinolysis
within a thrombus (Boulaftali et al., 2011). Moreover, PN-1 forms
covalent complexes with its target proteases, which are cleared by
endocytosis, mainly via the LDL receptor-related protein-1 (LRP-
1), a member of the scavenger receptor family (Knauer et al.,
1997, 1999; Muhl et al., 2007; Lillis et al., 2008).
LRP-1 is a multifunctional cell surface receptor expressed in
a wide range of cells, including vSMCs (Moestrup et al., 1992)
and macrophages (Lillis et al., 2015). LRP-1 is implicated in
endocytosis and the uptake ofmultiple ligands via its extracellular
domain, and signal transduction via its intracytoplasmic domain
(Boucher and Gotthardt, 2004). Its large variety of extracellular
ligands and cytoplasmic signaling means that LRP-1 plays a role
in arterial wall physiology and pathology (Emonard et al., 2014).
Specific knockout of LRP in vSMCs (LRPsmc −/−) on an LDL
receptor (LDLR)−/− background in mice is highly pathogenic,
leading to an exacerbation of atherosclerosis (Boucher et al.,
2003, 2007). LRP-1 is also a scavenger receptor responsible for the
uptake of LDL, especially aggregated LDL, leading to intracellular
accumulation of lipids and transformation of vSMCs (Llorente-
Cortes et al., 2006, 2007) and monocyte-derived macrophages
(Llorente-Cortes et al., 2007; Lillis et al., 2015) into foam cells in
human atheroma.
Our hypothesis is that protease-PN-1 complexes could be
engulfed via LRP-1 in foam cells. This mechanism of protease-
antiprotease uptake and its consequences have not yet been
Abbreviations: Ag, aggregated; DAPI, 4, 6-DiAmidino-2-PhenylIndole; FL,
Fibrolipidic Lesions; FS, Fatty Streaks; GAGs, GlycosAminoGlycans; LDL, Low
Density Lipoprotein; LDLR, LDL receptor; LRP-1, LDL receptor-related protein-
1; PAI-1, Plasminogen Activator Inhibitor-1; PN-1, Protease Nexin-1; RAP,
Receptor Associated Protein; TGFβ, Transforming Growth Factor β; TIMPs,
Tissue Inhibitors of MetalloProteinases; t-PA, tissue Plasminogen Activator;
vSMCs, vascular Smooth Muscle Cells.
extensively explored in the human arterial wall ex vivo and
particularly at the early stage of atheroma. The aim of the present
study was to investigate the internalization of plasmin-PN-1
complexes by vSMCs in early human atheroma via the LRP-1
scavenger receptor. A unique collection of early stages of human
atheroma, involving normal aorta, fatty streaks, and fibrolipidic
initial plaques, provides us the opportunity to decipher plasmin
activation and the internalization of plasmin-PN-1complexes in
this context.
MATERIALS AND METHODS
Patients and Aortic Specimens
The atherosclerotic samples (n = 31) and healthy aortas (n =
12) were obtained from anonymous deceased organ donors with
the authorization of the French Biomedicine Agency (PFS 09-
007) and in accordance with the Declaration of Helsinki. The
clinical data associated with this series of patients are reported
in Table 1. The healthy aortas were macroscopically devoid of
early atheroma, whereas the others presented fatty streaks (FS) or
fibrolipidic lesions (FL), defined by subendothelial accumulation
of lipids (yellow), capped (FL) or not (FS) by areas of cell
proliferation (which appear white). Aortic tissue preparation
consisted of an immediate macroscopic dissection to remove the
adventitial layer and to separate intima from media, followed by
either direct freezing or enzymatic digestion for vSMC primary
cultures.
Aortic Tissue Extracts and Conditioned
Medium
Extractions (mRNA, protein) were performed from frozen aortic
media and intimal tissue after microdissection. The aortic layers
were first pulverized in liquid nitrogen using a Freezer mill.
Between 20 and 200mg of aortic powder was used for qPCR
and immunoblotting. The numbers of medial and intimal tissue
extracts were: healthy aortas (control): n= 7, intimal FS: n= 12,
medial FS: n= 9, intimal FL: n= 9, medial FL: n= 9.
Conditioned medium was obtained by incubation of small
pieces of healthy media, intima or media of FS and FL (24 h at
37◦C) in a standardized volume (6ml/g of sample wet weight)
of RPMI culture medium supplemented with antibiotics and
antimycotics.
TABLE 1 | Clinical characteristics of patients.
Healthy aorta Early atheroma
FS FL
N 12 18 13
Age (years) 48.7 ± 14.3 57.9 ± 19.2 65.6 ± 13.9
Sex, % male 70 39 54
The cohort of patients studied presented 2 groups: patients with a healthy aorta and
those with early atheroma. FS: fatty streaks, FL: fibrolipidic lesions. Results are expressed
as means ± SD.
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Human vSMC Cultures/LDL Preparation
Samples of healthy aortic media were incubated for 3 h at 37◦C
in 0.3% collagenase (LifeTechnologies, Gif-sur-Yvette, France)
and 0.1% elastase (Worthington Biochemical Corporation,
Lakewood, New Jersey, USA) mixture to obtain primary cultures
of aortic vSMCs.
Cells were cultured in SMC Medium 2 from PromoCell
(Heidelberg, Germany) with 5% fetal calf serum (FCS). Passages
3 to 4 were used for experiments.
First, vSMCs were starved for 5 h and then incubated for
48 h with LDL or ag (aggregated) LDL at 100 µg/mL in
serum-free medium. Cells were then washed with PBS and
plasminogen was added to perform plasminogen activation
and plasmin assays for 48 h, or proteins were extracted for
immunoblotting. Human LDL particles were obtained from
pooled plasma of normocholesterolemic volunteers and isolated
by sequential ultracentrifugation. The native LDL was conserved
in the presence of antioxidants to avoid oxidation before addition
to the cells. agLDL was generated by vortexing LDL as previously
described (Llorente-Cortes et al., 2000).
Immunohistochemistry
Atherosclerotic and healthy aortic tissue sections were obtained
from paraformaldehyde-fixed, non-complicated plaques, and
healthy wall as previously described (Mansilla et al., 2008).
Sections were treated for antigen retrieval by heating in a
microwave in citrate buffer, pH 6 and the endogenous peroxidase
quenched with 3% hydrogen peroxide. Non-specific binding was
blocked using PBS-Tween 20 (PBS-T) with 5% BSA for 1 h at
room temperature.
Normal and atherosclerotic aortas were incubated overnight
with the following antibodies: mouse anti-human PN-1 (1:800,
in house Mansilla et al., 2008), goat anti-human LRP-1 (1:80,
Santa Cruz Biotechnology, Dallas, Texas, USA), mouse anti-
human plasminogen (1:80, Santa Cruz Biotechnology), rabbit
anti-human t-PA (1:30, Santa Cruz Biotechnology), rabbit anti-
human annexin A2 (1:50, Santa Cruz Biotechnology), goat anti-
human P-Selectin (1:50, Santa Cruz Biotechnology), mouse anti-
human CD68 (1:100, Dako, les Ulis, France), goat anti-human
SM22α (1:200, Abcam, Paris, France), and mouse anti-human α
actin (1:50, Dako).
All slides were incubated with secondary antibody conjugated
with peroxidase (LSAB-DAKO Kit) for 30 min and revealed
by H2O2-dependent oxidation of DAB (3, 3′-diaminobenzidine)
precipitation (brown).
The slides were counterstained with Mayer’s hematoxylin.
For the negative controls, the primary antibody was replaced by
an isotype-matched non-specific IgG at the same concentration.
As plaques are autofluorescent at multiple wavelengths,
it is difficult to discriminate specific signals from the
autofluorescent background. Therefore, double fluorescent
immunohistochemical staining was not performed in the present
study.
Real-Time qPCR
Total RNA was extracted from frozen samples of aortic intima
and media (Healthy aortic media (control), intima and media







of FS, intima and media of FL) using the RNeasy R© Tissue Mini
Kit (Qiagen, les Ulis, France) according to the manufacturer’s
instructions. Reverse transcription was performed using the
Maxima First Strand cDNA Synthesis kit (Thermo Scientific,
Illkrich, France). Human PN-1, LRP-1, and t-PA mRNA levels
were analyzed by real-time qPCR with SYBR Green detection
(BioRad, Marnes-la-Coquette, France).
Primer sequences used to perform real-time qPCR are
indicated in Table 2. The mRNA levels were normalized to
human HPRT-1 (hypoxanthine phosphoribosyltransferase -1)
mRNA.
Western Blot
Frozen pulverized aortic intimal and medial tissues or cultured
vSMCs were homogenized in lysis buffer (50 mM Tris, 150
mM NaCl, 5 mM EDTA, 1% Triton-X, 0.1% SDS) containing a
cocktail of protease inhibitors, P8340 (Sigma Aldrich, St Louis,
MO, USA). The lysates were clarified by centrifugation (15, 000 g,
20min at 4◦C) and protein concentration of each sample was
determined by BCA protein assay (Thermo Scientific). Proteins
of human tissue (15µg) or cultured vSMCs (4µg) were separated
by 4–20% (PN1) and 10% (LRP-1, t-PA) SDS-polyacrylamide gels
under non-reducing conditions.
Proteins were transferred to a nitrocellulose membrane
(Hybond, Amersham Biosciences, Illkrich, France) and then
blocked in 5% low fat milk-PBS-T or 4% fish gelatin-PBS-T
for 1 h. Membranes were incubated overnight at 4◦C with the
following primary antibodies: rabbit anti-human PN-1 (1:600, in
house), mouse anti-human LRP-1 (1:250, Sigma-Aldrich), and
mouse anti-human t-PA (1:250, Abcam). The secondary antibody
used was a mouse (Sigma-Aldrich) or a rabbit IgG conjugated
with peroxidase (Jackson ImmunoResearch Labs, PA, USA) for
1 h at room temperature. Detection by chemiluminescence was
performed using the ECL+ (enhanced chemiluminescence) kit
from Amersham Biosciences.
Plasminogen Activation and Plasmin Assay
One hundred microliters of conditioned medium from tissue of
healthy media, intima, and media FS and FL was added in 96-
well plates. vSMCs were grown to confluence and incubated with
or without native or aggregated LDL for 48 h, in the presence
of different concentrations of human plasminogen (0, 125, 250,
500 nM) from Cryopep (Montpellier, France). The plasmin
selective fluorescent substrate was added [MeOSuc-Ala-Phe-Lys-
AMC (trifluoroacetate salt), 40 µM; Bachem, Weil am Rhein,
Germany] to the cells and conditioned medium. Fluorescence
emission kinetics were measured at 460 nm after 380 nm
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FIGURE 1 | Cellular localization of plasminogen/plasmin, PN-1, LRP-1, CD68, α actin, and transgelin (SM 22α) in intima of fatty streaks (FS). Histological
sections of healthy aortas and serial sections of FS. Immunostaining of plasminogen/plasmin in healthy aortas (A) and FS (D). Immunosignal of PN-1 in healthy aortas
(B), FS (E). Immunosignal of LRP-1 in healthy aortas (C) and FS (F). Phagocytosis marker (CD 68) staining (G). Smooth muscle cell marker staining [(α actin, H) and
(SM 22α, I)]. The negative control is shown in Figure 2A.
excitation with a Tecan monochromator infinite R©M200 pro.
Plasmin formation was calculated from the rates of fluorescence
emission/second. Each experiment was performed in triplicate.
Cell Biology
Primary human vSMC cultures were grown in 48-well plates or
8-well chamber slides and incubated with PN-1 alone (125 nM,
in house), plasmin alone (25 nM, American diagnostic inc,
Connecticut, USA) or PN-1 and plasmin together which were
pre-incubated for 1 h at 37◦C to allow complex formation,
without or with RAP (Receptor associated protein) (50 µg/ml,
Molecular innovation, Michigan, USA) and added to vSMCs for
2 h at 37◦C.
First, cells were washed with PBS and fixed in PBS
containing 3.7% paraformaldehyde, then permeabilized with
0.1% Triton X-100 (Sigma-Aldrich) in PBS. Cells were blocked
with 5% BSA in PBS and incubated with the following
primary antibodies: rabbit anti-human PN-1 (1:600, in house),
mouse anti-LRP-1 (1:250, Sigma-Aldrich), and mouse anti-
plasmin/plasminogen (1:50, Thermo Scientific); this latter was
used to detect both plasmin alone and plasmin-PN-1 complexes.
Alexa Fluor R©488 and 555-labeled (Life Technologies) secondary
antibodies were used for visualization. Finally cells were washed
and incubated with DAPI (4, 6-diamidino-2-phenylindole)
to stain the nuclei. Staining was visualized using a Leica
fluorescence microscope or a Zeiss LSM 780 confocal microscope
and images were analyzed with the Zen Lite 2012 software
(France).
Statistical Analysis
Values are expressed as means ± SEM, the number of samples
(n) is indicated in the figure legends. Since, despite the small
number of experiments, point dispersion was limited, cell biology
experiments are represented by histograms and the difference
between groups was tested using a paired t-test. Tissue data are
represented by dot plots and the differences between twomedians
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FIGURE 2 | Platelet PN-1 and fatty streaks (FS). Serial sections of FS. IgG (negative control, A). Immunosignal of PN-1 in FS (B,D,E) and in luminal platelet
aggregates (D,E,F). Immunosignal of p-selectin (C).
tested using the non-parametric Mann-Whitney test (Prism 5,
GraphPad software). Differences between groups are considered
statistically significant when p < 0.05.
RESULTS
Tissue Biology of Plasmin(Ogen), PN-1,
and LRP-1 in Early Stages of Human
Atherosclerosis
The atherosclerotic lesions were characterized macroscopically
and classified after histological examination by staining with
hematoxylin & eosin or Masson’s trichrome. The different stages
of atherosclerotic lesions were determined according to the
classification of Stary et al. (1995). Here we investigated two
stages of early atheroma, fatty streaks (FS, type II) and fibrolipidic
lesions, also named fibro-atheroma (FL, type IV).
The presence of plasminogen/plasmin, PN-1, and LRP-1 in
healthy aortas, and on serial sections of FS and FL, was analyzed
by immunohistochemistry. In healthy aortas, no positive staining
for plasminogen/plasmin was observed (Figure 1A). In contrast,
staining of PN-1 and LRP-1 was weak and always associated with
vSMCs in the media (Figures 1B,C).
Plasminogen/plasmin staining was detected in FS
especially in intimal foam cells (phagocytes, Figure 1D).
PN-1 immunostaining (Figure 1E) was intense and also
associated with intimal foam cells as revealed by CD68 staining
(Figure 1G) including vSMCs as revealed by vSMC markers,
α actin (Figure 1H) and SM-22α (Figure 1I). As observed for
PN-1, staining of LRP-1 was also increased in FS (Figure 1F) and
associated with intimal foam cells.
PN-1 was also associated with intimal platelets and cells
(Figures 2B,D) identified by P-selectin (Figure 2C). PN-1 was
cell-associated but also cell-independent and potentially released
by intraluminal fibrin-platelet aggregates as they contain large
amounts of PN-1 (Figures 2D–F).
In FL, the immunostaining of plasminogen (Figure 3B),
PN-1 (Figure 3C), and LRP-1 (Figure 3D) was intense and
associated with intimal cells including vSMCs in the fibrous
cap as revealed by the vSMC marker, SM 22α (Figure 3E).
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FIGURE 3 | Cellular localization of plasminogen/plasmin, PN-1, LRP-1, SM 22α, and CD68 in fibrolipidic lesions (FL). Serial sections of FL. IgG (negative
control, A). Plasminogen/plasmin staining (B). Immunosignal of PN-1 (C). Immunostaining of LRP-1 (D). Smooth muscle cell marker staining (SM 22α, E).
Phagocytosis marker (CD 68) staining (F).
The negative control is shown in Figure 3A. The acellular
lipid core was positive for plasminogen/plasmin (Figure 3B)
and was also occasionally positive for PN-1 (Figure 3C). LRP-
1 was less observed in the acellular lipid core (Figure 3D).
Phagocytes, revealed by CD68 were also observed in the
lipid core (Figure 3F). LRP-1 (Figure 3D) could be associated
with CD68 positivity (Figure 3F) particularly at the plaque
shoulder.
Serial sections of FS were used to demonstrate the presence
of proteins involved in the activation of the plasminergic
system in early atheroma. We could indeed detect positive
immunostaining for Annexin A2 (Figure 4A), t-PA (Figure 4B),
and plasminogen (Figure 4C) in FS associated with intimal foam
cells. These different proteins colocalized on the same platforms
and therefore can catalyze the formation of active plasmin on the
surface of cells. We also demonstrated an increase in plasmin
activity in conditioned medium of intimal FL as compared to
healthy media (Figure 4D).
PN-1 (Figure 5A) and LRP-1 mRNA (Figure 5C) were
increased in the intima of FL compared to healthy aortas, as
was t-PA mRNA in the intima of both FS and FL compared to
healthy aortas (Figure 5B). In contrast, plasminogen mRNA was
not detectable in these tissues, demonstrating the plasma-borne
origin of plasminogen detected by immunohistochemistry in FS
and FL.
Western blot analysis of tissue extracts derived from healthy
aortas and atherosclerotic plaques revealed that PN-1 protein
(Figures 5D,F) was barely detectable in normal aortas and
significantly accumulated in the intima and media of FS and FL.
The small difference between mRNA and protein extract
suggests that part of the PN-1 was not synthesized in situ, but
could be retained intracellularly.
Likewise, increased LRP-1 (Figures 5E,F) protein levels were
observed in the intima of FL as compared to healthy aortas.
In contrast, t-PA protein was undetectable in these aortic tissue
extracts.
vSMC Biology
a- Effect of Native and Aggregated (ag) LDL on
Plasmin Activity and the Expression of PN-1, t-PA,
and LRP-1 in vSMCs
LRP-1 is a scavenger receptor involved in both clearance of
serine protease-PN-1 complexes (Muhl et al., 2007) and in the
internalization of LDL (Llorente-Cortes et al., 2007). Because
of the modulation of the expression of PN-1, t-PA, and LRP-1
observed during the early stages of atheroma, we checked the
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FIGURE 4 | Colocalization of Annexin A2, t-PA, and plasminogen in serial sections of FS intima. Immunostaining of Annexin A2 (A), t-PA (B), and
plasminogen (C) in FS. White arrows indicate the area in which Annexin A2, t-PA, and plasminogen immunostaining were colocalized. Plasmin activity in conditioned
medium of healthy media, intima and media SL and FL (D): healthy media n = 10 vs. intima of FL n = 9; *p < 0.05. The non-parametric Mann-Whitney test was used.
effects of LDL and agLDL on the expression of PN-1, t-PA, and
LRP-1 and the potential consequences on the activation of the
fibrinolytic system.
For this purpose, we mimicked the pathological vascular
condition by using primary vSMCs, pretreated or not with LDL
or agLDL for 48 h.
Treatment of vSMCs with either LDL or agLDL induced
overexpression of PN-1 protein as compared to control
(Figures 6A,D). t-PA protein levels were also significantly
increased in the presence of both LDL and agLDL
(Figures 6B,D). In contrast, neither LDL nor agLDL affected
LRP-1 protein expression in vSMCs (Figures 6C,D).
The effect of LDL and agLDL on plasminogen activation was
investigated at the surface of vSMCs. Neither LDL nor agLDL
had any relevant effect on plasminogen activation whatever the
concentration of exogenous plasminogen added to the vSMCs
(Figure 6E).
b- Plasmin-PN-1 Complexes are Internalized by
LRP-1 in vSMCs, Whereas Plasmin Alone is Not
Internalized
PN-1 is known to be able to neutralize the enzymatic activities
of serine proteases by forming covalent complexes that can be
cleared by LRP-1 in the arterial wall. Therefore, we analyzed
the internalization of plasmin and PN-1 by LRP-1 in human
primary vSMC cultures by immunofluorescence and confocal
microscopy. The addition of PN-1 alone to vSMCs leads to
an intracellular accumulation of PN-1 (Figures 7A, 8A; green),
whereas the addition of plasmin alone was not followed by its
internalization by vSMCs (Figures 7B, 8B; red).
Plasmin-PN-1 complexes detected with an anti-plasmin
antibody (Figures 7C, 8C; red) or with both anti-PN-1 (green)
and anti-plasmin (red) antibodies (Figure 7D) were internalized
and accumulated in the cytosolic compartment. Co-staining
of plasmin-PN-1 complexes (Figure 7E; green) and LRP-1
(Figure 7E; red) shows the colocalization and the intracellular
accumulation of the protease, the serpin and the scavenger
receptor in vSMCs.
Incubation with RAP (Figures 7F,G, 8D,E), known as a LRP-1
antagonist, inhibited the internalization of PN-1 or plasmin-PN-
1 complexes in vSMCs.
DISCUSSION
Previous studies demonstrated that plasma proteins, such as LDL,
are radially convected through the arterial wall and retained by
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FIGURE 5 | PN-1 (A), tissue plasminogen activator (t-PA; B), and LRP-1(C) mRNA expression and PN-1 (D, F) and LRP-1 (E, F) protein expression in
human aortic tissues (healthy aortas, intima and media of FS, intima and media of FL). PN-1 (A): healthy media n = 6 vs. intima of FL n = 9; *p < 0.05, t-PA
(B): healthy media n = 6 vs. intima of FL n = 9; ***p < 0.001, intima of FS n = 10 vs. intima of FL n = 9; **p < 0.01, healthy media: n = 6 vs. intima of FS n = 10; *p <
0.05. LRP-1 (C): healthy media n = 7 vs. intima of FL n = 9; *p < 0.05. PN-1 protein expression (D,F): healthy media n = 6 vs. intima of FS n = 12; **p < 0.01, vs.
media of FS n = 7; ***p < 0.001, vs. intima of FL n = 9; *p < 0.05, vs. media of FL n = 6; **p < 0.01. LRP-1 protein (E,F): healthy media n = 6 vs. intima of FL n = 9;
*p < 0.05. The non-parametric Mann-Whitney test was used. There was no loading control because intima of advanced lesions is acellular and there are no
appropriate stable housekeeping proteins.
its components (Tabas et al., 2007), and that the fibrinolytic
system is activated in vitro in contact with vSMCs (Meilhac et al.,
2003) and in vivo during development of atherosclerotic plaques
(Bauriedel et al., 1999; Rossignol et al., 2006). In this study, we
explored the source, the activation, and the uptake of plasmin
in the arterial wall of early atheroma. Since plasminogen is not
synthesized within the arterial wall, circulating plasminogen is
delivered to it by transmural convection from plasma according
to the pressure gradient existing between the lumen and the
adventitial layer (Tedgui and Lever, 1987; Michel et al., 2007).
We showed that plasminogen, t-PA, and Annexin A2 colocalize
in the same area of early atheroma, providing evidence of the
existence of a vSMC platform able to activate plasminogen
within the wall. In contrast to healthy aortas, we showed
that an active fibrinolytic system is present in early atheroma.
Plasminogen and t-PA potentially form quaternary complexes
with the Annexin A2-S100 protein tetramer on the vSMC
surface, which acts as a bridge between plasminogen and t-PA
leading to the production of active plasmin (Madureira et al.,
2011). We also showed the presence of proteolytic stress caused
by plasmin in the intima of early atheroma. The proteolytic
activity of cell-mediated plasmin generation could participate in
atherosclerotic development, vSMC migration and rarefaction
in the arterial wall (Torzewski et al., 2004; Rossignol et al.,
2006).
PAI-1 and PN-1 are the principal tissue serpins able to
block the plasminergic system in the arterial wall at different
levels (Bouton et al., 2012). Contrasting with PAI-1 and α2-
antiplasmin, PN-1 is not diffusible, and is the main serpin
within the arterial wall, always associated with GAGs and barely
detectable in the plasma (Richard et al., 2006; Bouton et al.,
2012). PN-1 is a key cell-associated serpin expressed by platelets,
macrophages (Mansilla et al., 2008), endothelial cells, vSMCs, and
fibroblasts (Bouton et al., 2012). In this study, we investigated
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FIGURE 6 | Effects of native and aggregated (ag) LDL on PN-1 (A,D), t-PA (B,D), LRP-1 (C,D) protein expression and plasminogen activation (E) in
vSMCs. The results are expressed relative to control for each experiment. PN-1 protein expression (A,D): LDL 1.62 ± 0.30, agLDL 1.60 ± 0.21; **p < 0.01, n = 5.
t-PA protein expression (B,D): LDL 1.82 ± 0.26, agLDL 1.78 ± 0.46; *p < 0.05, n = 5. LRP-1 (C,D) protein expression (n = 5). The plasminogen activation (n = 3 and
each experiment done in triplicate) at the surface of vSMCs (E). The paired t-test was used.
the source of PN-1 in early human atheroma and the ability of
vSMCs to internalize plasmin-PN-1 complexes. Using human FS
and FL, we identified both adherent platelets and intimal foams
cells, including vSMCs, as themain sites of PN-1 presence in early
atheroma.
Our results also showed an increase in both mRNA and
protein levels of PN-1 associated with the intima in early human
atheroma. Plasmin is one of the main proteases responsible for
the release of active TGF-β (Jenkins, 2008) which is a powerful
inducer of PN-1 expression (Gomez et al., 2013). Therefore, TGF-
β could be a link between plasmin and PN-1 in early atheroma. In
this context, PN-1 is not only overexpressed by intimal foam cells,
but also released by aggregated platelets and therefore retained
by the GAG-rich intima (Wight, 1985). These results are in
agreement with those showing that PN-1 expression correlates
with the different stages of evolution of atherosclerosis (Mansilla
et al., 2008) and the fact that subendothelial adherent platelets are
early initial events in atheroma (Massberg et al., 2002). Mansilla
et al (Mansilla et al., 2008) suggested that the major sources
of PN-1 in vulnerable plaques were platelets and observed a
considerable enrichment of PN-1 in phagocytes (CD68+ cells).
vSMCs can also acquire a macrophage-like phenotype due
to their plasticity, including CD68 positivity associated with
phagolysosome activities (Lacolley et al., 2012; Michel et al.,
2012). Therefore, foams cells, including vSMCs, can potentially
assume the role of endocytosis of plasmin-PN-1 complexes in the
arterial wall.
LRP-1 is a member of the LDL scavenger receptor family
implicated in the uptake of multiple ligands (Boucher and
Gotthardt, 2004).
LRP-1 is expressed in normal healthy vascular tissues,
associated with vSMCs in the media of mammary arteries,
suggesting that it is involved in physiological processes (Lupu
et al., 1994). LRP-1 is also highly expressed within human
atherosclerotic lesions (Luoma et al., 1994).
Our immunohistochemical and biochemical data obtained in
FS and FL show that the expression of the scavenger receptor,
LRP-1, is increased in these lesions, and is associated with
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FIGURE 7 | Internalization of PN-1, plasmin, and plasmin-PN-1 complexes in vSMCs. PN-1 alone (125 nM, A,F), plasmin alone (25 nM, B), and pre-formed
plasmin-PN-1 complexes (C,D,E,G) were added to vSMCs for 2 h at 37◦C without (A–E) or with RAP (50 µg/ml, F,G). After cell permeabilization, PN-1 alone (A,F)
was detected by Alexa Fluor488-labeled secondary antibody (green), plasmin alone (B) by Alexa Fluor®555-labeled secondary antibody (red) and nuclei by DAPI
staining (blue). Plasmin-PN-1 complexes were revealed with plasmin antibody and detected by Alexa Fluor®555-labeled secondary antibody (C,G, red) or PN-1 and
plasmin antibodies and detected with Alexa Fluor®488 (D, green) and 555-labeled secondary antibody (D, red) respectively. Yellow color and white arrows highlight
examples of intracellular co-localization of plasmin-PN-1 complexes revealed with PN-1 and plasmin antibodies (D). LRP-1 was detected with Alexa
Fluor®555-labeled secondary antibody (E, red), plasmin-PN-1 complexes were revealed with plasmin antibody and detected by Alexa fluor®488-labeled secondary
antibody (E, green). Yellow color and white arrows indicate the intracellular colocalization of LRP-1 and plasmin-PN-1 complexes (E).
intimal foam cells. Previous studies showed that LRP-1 was up-
regulated in macrophage-derived foam cells and proliferating
vSMCs in the aorta of rabbits fed a high-cholesterol diet, two
cell types involved in the development of atherosclerotic lesions
(Watanabe et al., 1994; Boucher and Gotthardt, 2004). The use of
mice deficient in SMC LRP (LRPsmc −/−) associated with LDLR
knockout (LDLR−/−) resulted in a severe vSMC proliferation
within the aorta, disruption of elastic laminae, and enhancement
of atherosclerosis, suggesting that vSMC LRP plays an important
atheroprotective role via clearance capacities not limited to LDL
endocytosis alone (Boucher et al., 2003).
vSMCs are the stromal cells of the arterial wall. They
support the initial lipid injury by the uptake and retention
via glycosaminoglycans of LDL, leading to foam cell formation
in the intimal layer of early atheroma (Parker and Odland,
1966; Goldstein et al., 1977; Katsuda et al., 1992; Kockx et al.,
1998; Owens et al., 2004; Michel et al., 2012; Allahverdian
et al., 2014; Feil et al., 2014; Shankman et al., 2015). LRP-1
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FIGURE 8 | Internalization of PN-1, plasmin, and plasmin-PN-1 complexes in vSMCs (confocal microscopy). PN-1 alone (125 nM, A,D), plasmin alone (25
nM, B), and pre-formed plasmin-PN-1 complexes (C,E) were added to vSMCs for 2 h at 37◦C without (A–C) or with RAP (50 µg/ml, D,E). After cell permeabilization,
PN-1 alone (A, D) was detected by Alexa Fluor®488-labeled secondary antibody (green), plasmin alone (B) and plasmin-PN-1 complexes (C,E) by Alexa
Fluor®555-labeled secondary antibody (red) and nuclei by DAPI staining (blue). White arrows indicate the intracellular localization of plasmin-PN-1 complexes (C). The
images are presented as maximum intensity projection of confocal microscopy.
is implicated in the selective uptake of cholesteryl esters of
aggregated LDL and the formation of lipid storage droplets in
human arterial vSMCs (Llorente-Cortes et al., 2006, 2007) and
monocyte-derived macrophages (Llorente-Cortes et al., 2007).
We observed that PN-1 and LRP-1 are up-regulated in the intima
of early atheroma. The LDL uptake by vSMCs (Llorente-Cortes
et al., 2006) could induce, at least in part, the overexpression
of PN-1 and LRP-1 that we observed in early atheroma. Our
data show that treatment of cultured vSMCs from healthy aortas
with LDL for 48 h increased protein levels of PN-1 and t-PA,
whereas it has no effect on LRP-1 protein, suggesting that LRP-
1 expression is constitutive in vSMCs whereas PN-1 and t-PA
are inducible. Moreover, we observed no change in plasmin
generation after incubation of cultured vSMCs with LDL and
exogenous plasminogen.
Besides its function in the selective uptake of LDL (Llorente-
Cortes et al., 2007), LRP-1 is also implicated in endocytosis of
protease-PN-1 complexes, and GAGs enhance the internalization
of thrombin-PN-1 complexes by stromal cells, leading to their
intracellular lysosomal degradation (Knauer et al., 1997, 1999;
Crisp et al., 2000; Lillis et al., 2008).
We showed that PN-1 alone and plasmin-PN-1 complexes
were internalized by cultured vSMCs, whereas plasmin
alone was not. Co-staining of plasmin-PN-1 complexes
and LRP-1 shows the intracellular colocalization of the
receptor and its ligands in the vSMCs. The use of the
specific LRP inhibitor, RAP, indicated that plasmin-
PN-1, and PN-1 alone are internalized via LRP-1 in
vSMCs.
This result is in accordance with Muhl et al. (2007)
who showed that application of FSAP (Factor VII activating
protease)-PN-1 complexes to vSMCs of mice resulted in
the intracellular accumulation of the complexes, but that
FSAP alone was not internalized and that the uptake of
this serine protease was a PN-1- and LRP-1-dependent
mechanism.
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CONCLUSION
Our study showed that the plasminergic system is activated
within the arterial intima in early atheroma. vSMCs and
platelets are the main sources of PN-1 in human atherosclerotic
lesions, but the endocytosed form of PN-1 is observed, at
least partly, in intimal foam cells. These data suggest that
tissue serpins could participate in the clearance capacities of
the arterial wall. We also showed that intimal LDL uptake,
which is a key process in the pathophysiology of early
atheroma, could be responsible for the up-regulation of PN-
1 levels in vSMCs. We demonstrated that human aortic
vSMCs internalize plasmin-PN-1 complexes and neutralize
the deleterious effects of plasmin on vSMCs (Meilhac et al.,
2003; Rossignol et al., 2004) via the scavenger receptor
LRP-1.
These results suggest that tissue PN-1 could limit, at least
in part, the plasmin-dependent proteolytic injury of the wall
by directly inhibiting plasmin, and by uptake of plasmin-PN-
1 complexes. Despite this potential protective effect of PN-1,
plasmin activity remains abnormally high in the intima of early
atheroma.
Finally, being the main structural and functional stromal
cell component of the arterial wall, vSMCs are also involved
in the activation, inhibition, and internalization of blood-borne
proteases by the arterial wall.
AUTHOR CONTRIBUTIONS
Design of study: KB, JM, and MB; conducting the experiments:
KB, LL; data analysis: KB; interpretation of the study data: KB,
RB, LB, YB, BH, VA, MB, and JM; writing and critical revision
of the manuscript: KB, RB, LB, YB, BH, VA, MB, and JM; final
approval of the version to be published: KB, RB, LB, LL, YB, BH,
VA, MB, and JM. KB, RB, LB, LL, YB, BH, VA, MB, and JM all
agree to be accountable for all aspects of the work in ensuring
that questions related to the accuracy or integrity of any part of
the work are appropriately investigated and resolved.
FUNDING
This work was supported by INSERM, Paris Diderot University
and a grant from the French National Research Agency [grant
number ANR-12-BSV1-0009 NEX-STARWall].
ACKNOWLEDGMENTS
The authors thank the surgeons of the departments of cardiac and
vascular surgery at Bichat Hospital and departments of liver and
digestive surgery of Beaujon Hospital for providing healthy and
pathological aortic samples, andMaryOsborne-Pellegrin for help
in editing. We also thank Hadidja Idhihar, Véronique Ollivier,
and Catherine Deschildre for their technical support.
REFERENCES
Allahverdian, S., Chehroudi, A. C., McManus, B. M., Abraham, T., and Francis,
G. A. (2014). Contribution of intimal smooth muscle cells to cholesterol
accumulation and macrophage-like cells in human atherosclerosis. Circulation
129, 1551–1559. doi: 10.1161/CIRCULATIONAHA.113.005015
Bauriedel, G., Hutter, R., Welsch, U., Bach, R., Sievert, H., and Luderitz, B.
(1999). Role of smooth muscle cell death in advanced coronary primary
lesions: implications for plaque instability. Cardiovasc. Res. 41, 480–488. doi:
10.1016/S0008-6363(98)00318-6
Borges, L. F., Gomez, D., Quintana, M., Touat, Z., Jondeau, G., Leclercq, A.,
et al. (2010). Fibrinolytic activity is associated with presence of cystic medial
degeneration in aneurysms of the ascending aorta. Histopathology 57, 917–932.
doi: 10.1111/j.1365-2559.2010.03719.x
Boucher, P., and Gotthardt, M. (2004). LRP and PDGF signaling: a
pathway to atherosclerosis. Trends Cardiovasc. Med. 14, 55–60. doi:
10.1016/j.tcm.2003.12.001
Boucher, P., Gotthardt, M., Li, W. P., Anderson, R. G., and Herz, J. (2003). LRP:
role in vascular wall integrity and protection from atherosclerosis. Science 300,
329–332. doi: 10.1126/science.1082095
Boucher, P., Li, W. P., Matz, R. L., Takayama, Y., Auwerx, J., Anderson, R. G.,
et al. (2007). LRP1 functions as an atheroprotective integrator of TGFbeta and
PDFG signals in the vascular wall: implications for Marfan syndrome. PLoS
ONE 2:e448. doi: 10.1371/journal.pone.0000448
Boulaftali, Y., Ho-Tin-Noe, B., Pena, A., Loyau, S., Venisse, L., Francois,
D., et al. (2011). Platelet protease nexin-1, a serpin that strongly
influences fibrinolysis and thrombolysis. Circulation 123, 1326–1334. doi:
10.1161/CIRCULATIONAHA.110.000885
Bouton, M. C., Boulaftali, Y., Richard, B., Arocas, V., Michel, J. B., and Jandrot-
Perrus, M. (2012). Emerging role of serpinE2/protease nexin-1 in hemostasis
and vascular biology. Blood 119, 2452–2457. doi: 10.1182/blood-2011-10-
387464
Bouton, M. C., Richard, B., Rossignol, P., Philippe, M., Guillin, M. C., Michel, J. B.,
et al. (2003). The serpin protease-nexin 1 is present in rat aortic smooth muscle
cells and is upregulated in L-NAME hypertensive rats. Arterioscler. Thromb.
Vasc. Biol. 23, 142–147. doi: 10.1161/01.ATV.0000047867.98019.2D
Caro, C. G. (2009). Discovery of the role of wall shear in
atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 29, 158–161. doi:
10.1161/ATVBAHA.108.166736
Caro, C. G., and Lever, M. J. (1984). Factors influencing arterial wall mass
transport. Biorheology 21, 197–205.
Crisp, R. J., Knauer, D. J., and Knauer, M. F. (2000). Roles of the heparin and
low density lipid receptor-related protein-binding sites of protease nexin 1
(PN1) in urokinase-PN1 complex catabolism. The PN1 heparin-binding site
mediates complex retention and degradation but not cell surface binding or
internalization. J. Biol. Chem. 275, 19628–19637. doi: 10.1074/jbc.M909172199
Didiasova, M., Wujak, L., Wygrecka, M., and Zakrzewicz, D. (2014). From
plasminogen to plasmin: role of plasminogen receptors in human cancer. Int. J.
Mol. Sci. 15, 21229–21252. doi: 10.3390/ijms151121229
Emonard, H., Theret, L., Bennasroune, A. H., and Dedieu, S. (2014).
Regulation of LRP-1 expression: make the point. Pathol. Biol. 62, 84–90. doi:
10.1016/j.patbio.2014.02.002
Feil, S., Fehrenbacher, B., Lukowski, R., Essmann, F., Schulze-Osthoff, K., Schaller,
M., et al. (2014). Transdifferentiation of vascular smooth muscle cells to
macrophage-like cells during atherogenesis. Circ. Res. 115, 662–667. doi:
10.1161/CIRCRESAHA.115.304634
Goldstein, J. L., Anderson, R. G., Buja, L. M., Basu, S. K., and Brown, M. S. (1977).
Overloading human aortic smooth muscle cells with low density lipoprotein-
cholesteryl esters reproduces features of atherosclerosis in vitro. J. Clin. Invest.
59, 1196–1202. doi: 10.1172/JCI108744
Gomez, D., Kessler, K., Borges, L. F., Richard, B., Touat, Z., Ollivier, V., et al. (2013).
Smad2-dependent protease nexin-1 overexpression differentiates chronic
aneurysms from acute dissections of human ascending aorta. Arterioscler.
Thromb. Vasc. Biol. 33, 2222–2232. doi: 10.1161/ATVBAHA.113.301327
Frontiers in Physiology | www.frontiersin.org 12 June 2016 | Volume 7 | Article 273
Boukais et al. Protease Nexin-1 and Early Atheroma
Jenkins, G. (2008). The role of proteases in transforming growth
factor-beta activation. Int. J. Biochem. Cell Biol. 40, 1068–1078. doi:
10.1016/j.biocel.2007.11.026
Katsuda, S., Boyd, H. C., Fligner, C., Ross, R., and Gown, A. M. (1992). Human
atherosclerosis. III. Immunocytochemical analysis of the cell composition of
lesions of young adults. Am. J. Pathol. 140, 907–914.
Knauer, M. F., Crisp, R. J., Kridel, S. J., and Knauer, D. J. (1999). Analysis of a
structural determinant in thrombin-protease nexin 1 complexes that mediates
clearance by the low density lipoprotein receptor-related protein. J. Biol. Chem.
274, 275–281. doi: 10.1074/jbc.274.1.275
Knauer, M. F., Kridel, S. J., Hawley, S. B., and Knauer, D. J. (1997). The efficient
catabolism of thrombin-protease nexin 1 complexes is a synergistic mechanism
that requires both the LDL receptor-related protein and cell surface heparins. J.
Biol. Chem. 272, 29039–29045. doi: 10.1074/jbc.272.46.29039
Kockx, M. M., De Meyer, G. R., Muhring, J., Jacob, W., Bult, H., and
Herman, A. G. (1998). Apoptosis and related proteins in different
stages of human atherosclerotic plaques. Circulation 97, 2307–2315. doi:
10.1161/01.CIR.97.23.2307
Lacolley, P., Regnault, V., Nicoletti, A., Li, Z., andMichel, J. B. (2012). The vascular
smooth muscle cell in arterial pathology: a cell that can take on multiple roles.
Cardiovasc. Res. 95, 194–204. doi: 10.1093/cvr/cvs135
Lillis, A. P., Muratoglu, S. C., Au, D. T., Migliorini, M., Lee, M. J., Fried,
S. K., et al. (2015). LDL Receptor-Related Protein-1 (LRP1) regulates
cholesterol accumulation in macrophages. PLoS ONE 10:e0128903. doi:
10.1371/journal.pone.0128903
Lillis, A. P., Van Duyn, L. B., Murphy-Ullrich, J. E., and Strickland, D.
K. (2008). LDL receptor-related protein 1: unique tissue-specific functions
revealed by selective gene knockout studies. Physiol. Rev. 88, 887–918. doi:
10.1152/physrev.00033.2007
Llorente-Cortes, V., Martinez-Gonzalez, J., and Badimon, L. (2000). LDL receptor-
related protein mediates uptake of aggregated LDL in human vascular
smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 20, 1572–1579. doi:
10.1161/01.ATV.20.6.1572
Llorente-Cortes, V., Otero-Vinas, M., Camino-Lopez, S., Costales, P., and
Badimon, L. (2006). Cholesteryl esters of aggregated LDL are internalized by
selective uptake in human vascular smooth muscle cells. Arterioscler. Thromb.
Vasc. Biol. 26, 117–123. doi: 10.1161/01.ATV.0000193618.32611.8b
Llorente-Cortes, V., Royo, T., Juan-Babot, O., and Badimon, L. (2007). Adipocyte
differentiation-related protein is induced by LRP1-mediated aggregated LDL
internalization in human vascular smooth muscle cells and macrophages. J.
Lipid Res. 48, 2133–2140. doi: 10.1194/jlr.M700039-JLR200
Luoma, J., Hiltunen, T., Sarkioja, T., Moestrup, S. K., Gliemann, J., Kodama,
T., et al. (1994). Expression of alpha 2-macroglobulin receptor/low density
lipoprotein receptor-related protein and scavenger receptor in human
atherosclerotic lesions. J. Clin. Invest. 93, 2014–2021. doi: 10.1172/JCI117195
Lupu, F., Heim, D., Bachmann, F., and Kruithof, E. K. (1994). Expression
of LDL receptor-related protein/alpha 2-macroglobulin receptor in human
normal and atherosclerotic arteries. Arterioscler. Thromb. 14, 1438–1444. doi:
10.1161/01.ATV.14.9.1438
Madureira, P. A., Surette, A. P., Phipps, K. D., Taboski, M. A., Miller, V. A.,
and Waisman, D. M. (2011). The role of the annexin A2 heterotetramer
in vascular fibrinolysis. Blood 118, 4789–4797. doi: 10.1182/blood-2011-06-3
34672
Mansilla, S., Boulaftali, Y., Venisse, L., Arocas, V., Meilhac, O., Michel, J. B., et al.
(2008). Macrophages and platelets are the major source of protease nexin-1 in
human atherosclerotic plaque. Arterioscler. Thromb. Vasc. Biol. 28, 1844–1850.
doi: 10.1161/ATVBAHA.108.171389
Massberg, S., Brand, K., Gruner, S., Page, S., Muller, E., Muller, I., et al. (2002).
A critical role of platelet adhesion in the initiation of atherosclerotic lesion
formation. J. Exp. Med. 196, 887–896. doi: 10.1084/jem.20012044
Meilhac, O., Ho-Tin-Noe, B., Houard, X., Philippe, M., Michel, J. B., and Angles-
Cano, E. (2003). Pericellular plasmin induces smooth muscle cell anoikis.
FASEB J. 17, 1301–1303. doi: 10.1096/fj.02-0687fje
Michel, J. B., Li, Z., and Lacolley, P. (2012). Smooth muscle cells and vascular
diseases. Cardiovasc. Res. 95, 135–137. doi: 10.1093/cvr/cvs172
Michel, J. B., Thaunat, O., Houard, X., Meilhac, O., Caligiuri, G., and Nicoletti,
A. (2007). Topological determinants and consequences of adventitial responses
to arterial wall injury. Arterioscler. Thromb. Vasc. Biol. 27, 1259–1268. doi:
10.1161/ATVBAHA.106.137851
Moestrup, S. K., Gliemann, J., and Pallesen, G. (1992). Distribution of the alpha
2-macroglobulin receptor/low density lipoprotein receptor-related protein in
human tissues. Cell Tissue Res. 269, 375–382. doi: 10.1007/BF00353892
Muhl, L., Nykjaer, A., Wygrecka, M., Monard, D., Preissner, K. T., and Kanse, S.
M. (2007). Inhibition of PDGF-BB by Factor VII-activating protease (FSAP)
is neutralized by protease nexin-1, and the FSAP-inhibitor complexes are
internalized via LRP. Biochem. J. 404, 191–196. doi: 10.1042/BJ20061630
Owens, G. K., Kumar, M. S., and Wamhoff, B. R. (2004). Molecular regulation
of vascular smooth muscle cell differentiation in development and disease.
Physiol. Rev. 84, 767–801. doi: 10.1152/physrev.00041.2003
Parker, F., and Odland, G. F. (1966). A correlative histochemical, biochemical and
electron microscopic study of experimental atherosclerosis in the rabbit aorta
with special reference to the myo-intimal cell. Am. J. Pathol. 48, 197–239.
Richard, B., Arocas, V., Guillin, M. C., Michel, J. B., Jandrot-Perrus, M., and
Bouton, M. C. (2004). Protease nexin-1: a cellular serpin down-regulated by
thrombin in rat aortic smooth muscle cells. J. Cell. Physiol. 201, 138–145. doi:
10.1002/jcp.20103
Richard, B., Pichon, S., Arocas, V., Venisse, L., Berrou, E., Bryckaert, M., et al.
(2006). The serpin protease nexin-1 regulates vascular smooth muscle cell
adhesion, spreading, migration and response to thrombin. J. Thromb. Haemost.
4, 322–328. doi: 10.1111/j.1538-7836.2006.01710.x
Rossignol, P., Ho-Tin-Noe, B., Vranckx, R., Bouton, M. C., Meilhac, O.,
Lijnen, H. R., et al. (2004). Protease nexin-1 inhibits plasminogen activation-
induced apoptosis of adherent cells. J. Biol. Chem. 279, 10346–10356. doi:
10.1074/jbc.M310964200
Rossignol, P., Luttun, A., Martin-Ventura, J. L., Lupu, F., Carmeliet, P., Collen,
D., et al. (2006). Plasminogen activation: a mediator of vascular smooth muscle
cell apoptosis in atherosclerotic plaques. J. Thromb. Haemost. 4, 664–670. doi:
10.1111/j.1538-7836.2005.01765.x
Shankman, L. S., Gomez, D., Cherepanova, O. A., Salmon, M., Alencar, G. F.,
Haskins, R. M., et al. (2015). KLF4-dependent phenotypic modulation of
smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat.
Med. 21, 628–637. doi: 10.1038/nm.3866
Stary, H. C., Chandler, A. B., Dinsmore, R. E., Fuster, V., Glagov, S., Insull,
W. Jr., et al. (1995). A definition of advanced types of atherosclerotic
lesions and a histological classification of atherosclerosis. A report from
the Committee on Vascular Lesions of the Council on Arteriosclerosis,
American Heart Association. Arteriosc. Thromb. Vasc. Biol. 15, 1512–1531. doi:
10.1161/01.ATV.15.9.1512
Tabas, I., Williams, K. J., and Boren, J. (2007). Subendothelial lipoprotein retention
as the initiating process in atherosclerosis: update and therapeutic implications.
Circulation 116, 1832–1844. doi: 10.1161/CIRCULATIONAHA.106.676890
Tedgui, A., and Lever, M. J. (1987). Effect of pressure and intimal damage on
131I-albumin and [14C]sucrose spaces in aorta. Am. J. Physiol. 253(6 Pt 2),
H1530–H1539.
Torzewski, M., Suriyaphol, P., Paprotka, K., Spath, L., Ochsenhirt, V., Schmitt,
A., et al. (2004). Enzymatic modification of low-density lipoprotein in
the arterial wall: a new role for plasmin and matrix metalloproteinases
in atherogenesis. Arterioscler. Thromb. Vasc. Biol. 24, 2130–2136. doi:
10.1161/01.ATV.0000144016.85221.66
Watanabe, Y., Inaba, T., Shimano, H., Gotoda, T., Yamamoto, K., Mokuno,
H., et al. (1994). Induction of LDL receptor-related protein during
the differentiation of monocyte-macrophages. Possible involvement in
the atherosclerotic process. Arterioscler. Thromb. 14, 1000–1006. doi:
10.1161/01.ATV.14.6.1000
Wight, T. N. (1985). Proteoglycans in pathological conditions: atherosclerosis. Fed.
Proc. 44, 381–385.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Boukais, Bayles, Borges, Louedec, Boulaftali, Ho-Tin-Noé, Arocas,
Bouton and Michel. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) or licensor
are credited and that the original publication in this journal is cited, in accordance
with accepted academic practice. No use, distribution or reproduction is permitted
which does not comply with these terms.
Frontiers in Physiology | www.frontiersin.org 13 June 2016 | Volume 7 | Article 273
